When was Molecular Partners founded?

Molecular Partners was founded in 2004 and raised its 1st funding round 3 years after it was founded.

Where is Molecular Partners located?

Molecular Partners is headquartered in Zurich, Switzerland.

How many employees does Molecular Partners have?

As of Aug 31, 2026, the latest employee count at Molecular Partners is 142.

Is Molecular Partners a funded company?

Molecular Partners is a funded company, having raised a total of $59.9M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 14, 2007.

When was the latest funding round of Molecular Partners?

Molecular Partners' latest funding was a $***** Post IPO round on Jul 2020, with participation from 0 investor.

Where does Molecular Partners rank among its competitors?

Molecular Partners ranks 55th amongst 2524 active competitors, of which 863 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Molecular Partners?

Molecular Partners' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Molecular Partners - 2026 Company Profile, Team, Funding & Competitors

Molecular Partners is a public company based in Zurich (Switzerland), founded in 2004 by Christian Zahnd. It operates as a Developer of therapeutic solutions for treating multiple diseases. Molecular Partners has raised $59.9M in funding from Index Ventures. The company has 2524 active competitors, including 863 funded and 626 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of therapeutic solutions for treating multiple diseases. The company specializes in developing DARPin that is designed with ankyrin repeat proteins-based therapies for the treatment of severe or life-threatening diseases with an initial focus on oncology and ophthalmology. MP0250 is their most advanced oncology candidate and can be used for the treatment of solid tumors and hematological malignancies.

Key Metrics

Founded Year

2004

Location

Zurich, Switzerland

Stage

Public

Total Funding

$59.9M in 3 rounds

Latest Funding Round

Post IPO, Jul 2020, $*****

Investors

Index Ventures & 5 more

Ranked

55^th among 2524 active competitors

Employee Count

142 as on Aug 31, 2026

Similar Companies

AdvanCell & 103 more

Exit Details

Public

View Molecular Partners' full profile

Molecular Partners got listed on Nov 05, 2014.

Click here to take a look at Molecular Partners's IPO in detail

Molecular Partners has raised a total funding of $59.9M over 3 rounds. Its first funding round was on Aug 14, 2007. Molecular Partners has 6 institutional investors.

Here is the list of recent funding rounds of Molecular Partners:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 2020	5138790	Post IPO	3948320	3868537	1826215	8368533
Dec 15, 2009	6064194	Series B	9102000	1551353	3294511	Index Ventures & 4 more
Aug 14, 2007	2329014	Series A	7685699	5273894	Index Ventures	BB Biotech Ventures & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Molecular Partners's funding rounds and investors

The founders of Molecular Partners is Christian Zahnd.

Here are the details of Molecular Partners' key team members:

Christian Zahnd: Co-Founder of Molecular Partners.

View details of Molecular Partners's Founder profiles and Board Members

Molecular Partners' employee count trend

Molecular Partners has 142 employees as of Aug 26. Here is Molecular Partners's employee count trend over the years:

Employee count trend for Molecular Partners

Uncover Molecular Partners' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Molecular Partners include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Molecular Partners, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
55th	Molecular Partners 2004, Zurich (Switzerland), Public	Developer of therapeutic solutions for treating multiple diseases	$59.9M	Endeavour Vision, Index Ventures & 4 others	65/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Molecular Partners's competitors? Click here to see the top ones

Molecular Partners has made no investments or acquisitions yet.

Here is the latest report on Molecular Partners's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to Molecular Partners

Media has covered Molecular Partners for a total of 18 events in the last 1 year, 15 of them have been about company updates and 1 about partnerships.